Previous 10 | Next 10 |
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced today pre-clinical data on AUTO6NG, the company’s next gene...
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, announced that the United States Food and Drug Administration (FDA) has gran...
LONDON, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2019 financial results and operational highl...
The Society for Immunotherapy of Cancer (SITC) will hold its annual scientific meeting from November 6 to 10 in National Harbor, Maryland. The latest results on promising new cancer therapies that work by harnessing the immune system will be presented. Here we look at three companies that will h...
LONDON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced changes to the company’s executive leadership team. Dr. Jim Faulkner, Senior Vice Pres...
LONDON, Oct. 03, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that pre-clinical data on AUTO6NG, the company’s next generation GD2-targeting CAR T c...
Autolus Therapeutics (NASDAQ: AUTL ) initiated with Buy rating and $26 (99% upside) price target at Needham. More news on: Autolus Therapeutics plc, Edwards Lifesciences Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...
Gainers : Pier 1 Imports (NYSE: PIR ) +28% . Endo International (NASDAQ: ENDP ) +24% . Autolus Therapeutics (NASDAQ: AUTL ) +25% . Microbot Medical (NASDAQ: MBOT ) +24% . Hovnanian Enterprises (NYSE: HOV ) +20% . Lannett Company (NYSE: LCI ) +20% . DocuSign (NASDAQ: DOCU ) +19% . Su...
The following slide deck was published by Autolus Therapeutics plc in conjunction with this Read more ...
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a single dose of AUTO1 LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...